Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Sponsor: Soleno Therapeutics, Inc.
A PHASE3 clinical study on Prader-Willi Syndrome, this trial is completed. The trial is conducted by Soleno Therapeutics, Inc. and has accumulated 16 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2023 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 11 earlier versions
-
Jul 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
May 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE3
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Soleno Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .